1. Beta-blocker use in patients with chronic obstructive pulmonary disease: A systematic review
- Author
-
Mark T. Dransfield, Kelly Qi Jia, Mohammed Ruzieh, Emily S Edwards, Lama Al Jebbawi, Aaron D Baugh, and Andrew Foy
- Subjects
COPD ,medicine.medical_specialty ,Heart disease ,business.industry ,medicine.drug_class ,Pulmonary disease ,Disease ,medicine.disease ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,Respiratory morbidity ,Medicine ,In patient ,Cardiology and Cardiovascular Medicine ,business ,Beta blocker - Abstract
Beta-blockers (βB) are a frequently used class of medications. Although βB have many indications, those related to cardiovascular disease are among the most common and important. However, in patients with chronic obstructive pulmonary disease (COPD), βB are used less often due to concerns about an unfavorable impact on respiratory morbidity and mortality. a need for well-designed randomized controlled trials to examine their safety and efficacy, particularly in patients with comorbid heart disease who otherwise have strong indications for βB.
- Published
- 2023
- Full Text
- View/download PDF